Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Accumulated Expenses for 15 consecutive years, with $26.3 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 26.65% year-over-year to $26.3 million; the TTM value through Mar 2026 reached $26.3 million, up 26.65%, while the annual FY2025 figure was $45.5 million, 2.99% down from the prior year.
  • Accumulated Expenses hit $26.3 million in Q1 2026 for Agios Pharmaceuticals, down from $45.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $46.9 million in Q4 2024 and bottomed at $19.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $31.8 million, with a median of $30.4 million recorded in 2022.
  • Year-over-year, Accumulated Expenses fell 21.28% in 2022 and then surged 42.23% in 2023.
  • Agios Pharmaceuticals' Accumulated Expenses stood at $30.4 million in 2022, then soared by 42.23% to $43.2 million in 2023, then rose by 8.56% to $46.9 million in 2024, then fell by 2.99% to $45.5 million in 2025, then tumbled by 42.16% to $26.3 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $26.3 million, $45.5 million, and $37.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.